Literature DB >> 11254492

GABA(B) receptors on vagal afferent pathways: peripheral and central inhibition.

E R Partosoedarso1, R L Young, L A Blackshaw.   

Abstract

To investigate GABA(B) receptors along vagal afferent pathways, we recorded from vagal afferents, medullary neurons, and vagal efferents in ferrets. Baclofen (7-14 micromol/kg i.v.) reduced gastric tension receptor and nucleus tractus solitarii neuronal responses to gastric distension but not gastroduodenal mucosal receptor responses to cholecystokinin (CCK). GABA(B) antagonists CGP-35348 or CGP-62349 reversed effects of baclofen. Vagal efferents showed excitatory and inhibitory responses to distension and CCK. Baclofen (3 nmol i.c.v. or 7-14 micromol/kg i.v.) reduced both distension response types but reduced only inhibitory responses to CCK. CGP-35348 (100 nmol i.c.v. or 100 micromol/kg i.v.) reversed baclofen's effect on distension responses, but inhibitory responses to CCK remained attenuated. They were, however, reversed by CGP-62349 (0.4 nmol i.c.v.). In conclusion, GABA(B) receptors inhibit mechanosensitivity, not chemosensitivity, of vagal afferents peripherally. Mechanosensory input to brain stem neurons is also reduced centrally by GABA(B) receptors, but excitatory chemosensory input is unaffected. Inhibitory mechano- and chemosensory inputs to brain stem neurons (via inhibitory interneurons) are both reduced, but the pathway taken by chemosensory input involves GABA(B) receptors that are insensitive to CGP-35348.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254492     DOI: 10.1152/ajpgi.2001.280.4.G658

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  19 in total

1.  Different in vitro and in vivo profiles of substituted 3-aminopropylphosphinate and 3-aminopropyl(methyl)phosphinate GABA(B) receptor agonists as inhibitors of transient lower oesophageal sphincter relaxation.

Authors:  A Lehmann; M Antonsson; A Aurell-Holmberg; L A Blackshaw; L Brändén; T Elebring; J Jensen; L Kärrberg; J P Mattsson; K Nilsson; S S Oja; P Saransaari; S von Unge
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  The Physiology of Eructation.

Authors:  Ivan M Lang
Journal:  Dysphagia       Date:  2015-12-22       Impact factor: 3.438

3.  Potentiation of mouse vagal afferent mechanosensitivity by ionotropic and metabotropic glutamate receptors.

Authors:  James A Slattery; Amanda J Page; Camilla L Dorian; Stuart M Brierley; L Ashley Blackshaw
Journal:  J Physiol       Date:  2006-08-31       Impact factor: 5.182

4.  A Randomized Double-Blind, Placebo-Controlled, Cross-Over Study Using Baclofen in the Treatment of Rumination Syndrome.

Authors:  Ans Pauwels; Charlotte Broers; Brecht Van Houtte; Nathalie Rommel; Tim Vanuytsel; Jan Tack
Journal:  Am J Gastroenterol       Date:  2017-12-05       Impact factor: 10.864

Review 5.  Peripheral neural targets in obesity.

Authors:  Amanda J Page; Erin Symonds; Madusha Peiris; L Ashley Blackshaw; Richard L Young
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 6.  Visceral pain: the neurophysiological mechanism.

Authors:  Jyoti N Sengupta
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Vagal sensory innervation of the gastric sling muscle and antral wall: implications for gastro-esophageal reflux disease?

Authors:  T L Powley; J M Gilbert; E A Baronowsky; C N Billingsley; F N Martin; R J Phillips
Journal:  Neurogastroenterol Motil       Date:  2012-08-27       Impact factor: 3.598

Review 8.  Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel?

Authors:  James Wise; Jeffrey L Conklin
Journal:  Curr Gastroenterol Rep       Date:  2004-06

9.  Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.

Authors:  A F Ciccaglione; L Marzio
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

10.  Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans.

Authors:  H Beaumont; J Jensen; A Carlsson; M Ruth; A Lehmann; Ge Boeckxstaens
Journal:  Br J Pharmacol       Date:  2008-12-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.